Company news
MacroGenics, Inc. news in 2024
MacroGenics, Inc.'s news releases, calls and decks from 2024, newest first.
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
November 4, 2024
MacroGenics Announces Leadership Transition
October 29, 2024
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
October 28, 2024
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
October 21, 2024
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 14, 2024
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 7, 2024
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
August 5, 2024
MacroGenics Provides Vobramitamab Duocarmazine Update
July 29, 2024
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
July 29, 2024
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
May 8, 2024
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 2, 2024
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 2, 2024
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
March 6, 2024
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
February 26, 2024
Calls in 2024
Decks in 2024
- Post-ESMO Conference Call (September 2024)
Conference · 23 slides · Sep 16, 2024
- Technical Presentation (May 2024)
Technical · 17 slides · May 9, 2024